Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHOICES trial of dirocaftor + posenacaftor + nesolicaftor in adults with cystic fibrosis and rare CFTR mutations
NL-OMON60286Phase 2Completed
- Sponsor
- University Medical Center Utrecht
- Start
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of dirocaftor, Posenacaftor and nesolicaftor in cystic fibrosis (CF) (2 arms), sponsored by University Medical Center Utrecht. Primary endpoint: Mean percent predicted forced expiratory volume in 1 second. Started May 2024; status: completed.
02
Drugs
dirocaftorPosenacaftornesolicaftor
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NL-OMON60286.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60286.